- Email: [email protected]
F161 Can the fast bone loss in osteoporotic patients be stopped with vitamin D metabolites as an alternative to estrogens?
PHYSICAL BONE MASS
ACTIVITY, IN HONG
CLIMACTERIC SYMPTOMS KONG PERIMENOPAUSAL
S C Ho, S G Chan, V Yip, C Chart, CL Law. Department of Community & Family Medicine, University of Hong Kong, Shatin, Hong Kong
AND WOMEN
CAN
THE FAST BONE LOSS IN OSTEOPOROTIC PATIENTS BE STOPPED WITH VITAMIN D METABOLITES AS AN ALTERNATIVE TO ESTROGENS?
MA. Dambacher, C. Merlin, M. NefJ University Clinic Balgrist and Center for Osteoporosis. (Switzerland)
the Chinese
This paper reports the pattern of physical activity and its relationship with climacteric symptoms and bone mass in perimenopausal women. Data were obtained from face to face interviews of 438 perimenopausal women recruited from a random telephone survey and the University Family Medicine Clinic. Physical activity was assessed based on the usual pattern of the previous week. Symptoms experienced in the previous two weeks were grouped into the broad categories of psychological and vasomotor complaints. Women with more number of psychological symptoms (maximum number = 6) spent less time in vigorous physical activity. They also walked a lower mean number of flights of stairs compared with women with fewer psychological complaints (p
Zurich.
Until now for the tailored prophylaxis and treatment of osteoporosis we used in slow bone losers anabolic substances like fluorides and in fast bone losers antiresorptive agents like estrogens. calcitonin and bisphosphonates. We designate fast bone losers as osteopcnic or osteoporotic patients with a loss of trahecular bone density in the radius of >3,5’/ calculated for one year. For this differentiation we use the high precise peripheral quantitative computed tomography DENSISCAN 1000 (p&T). which has a reproducibility in mixed collectives of 0,3%. The aim of this study was to evaluate whether vitamin D metabolites are also effective as antiresorptivc substances in fast bone losers, We started with 50 postmenopausal osteoporotic females. until now the results of the first 33 patients are available. The pretreatment phase lasted between 3 and 6 months and the treatment time of the same patients 9-12 months. fhe pretreatment bone loss and the treatment bone density changes were calculated for I year to compare the values. The pretreatment loss of trahecular bone density in the radius/year was 6.6 f 0.50/u (m i SEM), the boric “gain” under treatment with 0,5ug Calcitriol or I pg Alfacalcidol was + 0.01 % * 0.6 m f SEM RO.00 I Paired Student’s t test
Continued
F162
F161 (cant)
DIAGNOSIS DENSITOMETRIE before treatmen Loss of Trabecular Bone Density calculated for 1 year (FAST BONE LOSERS)
sRer treatment (lpg Alfaulcii, p < 0.001
1.: 0.: 4.: .,:: 2-i 41: 41 IT
OSTEOPOROSIS - COMPARATIVE PILOT STUDY
BY ULTRASOUND DATA FROM
A
MW Beckmann’, D Jap’, T Mohrmann’, R Bodden-Heidrich’, D Niederacher’, G Crombach’, D Langeneckhard$, C Ratjen’, HG Bender’; ‘Dept. Ob&Gyn, Heinrich-Heine-Universitat, Moorenstr. 5. 40225 Dusseldorf; 21nst. of Trace Elements Analytic, Schloss Tiirnich, PO Box 4 108.50 I.55 Kerpen, Germany.
0.5~ Caiciltil)
001
dd,
OF
Osteoporosis is a systemic bone disease with a decrease in bone structure and increased risk of fractures. For Germany 1995 in women > 65 years approximately 55.000 hip fractures with high morbidity and mortality depend on osteoporosis. The primary diagnosis of osteoporosis and the surveillance of therapeutic interventions is based either on laboratory parameter’s [i.e. alk. phosphatase (Al’), osteocalcin (OC), desoxypyridinolin (DP)] or on radiology [i.e. dual energy X-ray absorptiometry (DXA)]. In a pilot stud encompassing 433 persons [92 volunteers (42 female, 50 male); 34 I patients (101 pre-, 173 postmenopausal; 72 male)] the routine use of ultrasound osteodensitometrie (UD. Lunar AchillesTm) of the OS calcaneus was validated and tested. Velocity of the ultrasound signal (speed of sound = SOS) and the frequency attenuation (broadband ultrasound attenuation = BUA) were measured and a proprietary index (stiffness) calculated. UD data of different groups were analysed and compared with (1) anamnestic data, (2) routine laboratory data, (3) hormones (E2, Pg, FSH, LH, DHEAS, T), (4) bone metabolism parameters (AP, OC, DP), (5) trace elements in hairs (Ca, Gallium), (6) Vit. D and estrogen receptor polymorphism and (7) DXA measurements.
1
Conclusion Vitamin D Metabolites (Calcitriol or 1 Alfacalcidol) are highly effective in stopping the fast trabecular bone loss in postmenopausal osteoporotic women and are therefore an alternative to estrogens.
Continued
93
ACTIVITY, IN HONG
CLIMACTERIC SYMPTOMS KONG PERIMENOPAUSAL
S C Ho, S G Chan, V Yip, C Chart, CL Law. Department of Community & Family Medicine, University of Hong Kong, Shatin, Hong Kong
AND WOMEN
CAN
THE FAST BONE LOSS IN OSTEOPOROTIC PATIENTS BE STOPPED WITH VITAMIN D METABOLITES AS AN ALTERNATIVE TO ESTROGENS?
MA. Dambacher, C. Merlin, M. NefJ University Clinic Balgrist and Center for Osteoporosis. (Switzerland)
the Chinese
This paper reports the pattern of physical activity and its relationship with climacteric symptoms and bone mass in perimenopausal women. Data were obtained from face to face interviews of 438 perimenopausal women recruited from a random telephone survey and the University Family Medicine Clinic. Physical activity was assessed based on the usual pattern of the previous week. Symptoms experienced in the previous two weeks were grouped into the broad categories of psychological and vasomotor complaints. Women with more number of psychological symptoms (maximum number = 6) spent less time in vigorous physical activity. They also walked a lower mean number of flights of stairs compared with women with fewer psychological complaints (p
Zurich.
Until now for the tailored prophylaxis and treatment of osteoporosis we used in slow bone losers anabolic substances like fluorides and in fast bone losers antiresorptive agents like estrogens. calcitonin and bisphosphonates. We designate fast bone losers as osteopcnic or osteoporotic patients with a loss of trahecular bone density in the radius of >3,5’/ calculated for one year. For this differentiation we use the high precise peripheral quantitative computed tomography DENSISCAN 1000 (p&T). which has a reproducibility in mixed collectives of 0,3%. The aim of this study was to evaluate whether vitamin D metabolites are also effective as antiresorptivc substances in fast bone losers, We started with 50 postmenopausal osteoporotic females. until now the results of the first 33 patients are available. The pretreatment phase lasted between 3 and 6 months and the treatment time of the same patients 9-12 months. fhe pretreatment bone loss and the treatment bone density changes were calculated for I year to compare the values. The pretreatment loss of trahecular bone density in the radius/year was 6.6 f 0.50/u (m i SEM), the boric “gain” under treatment with 0,5ug Calcitriol or I pg Alfacalcidol was + 0.01 % * 0.6 m f SEM RO.00 I Paired Student’s t test
Continued
F162
F161 (cant)
DIAGNOSIS DENSITOMETRIE before treatmen Loss of Trabecular Bone Density calculated for 1 year (FAST BONE LOSERS)
sRer treatment (lpg Alfaulcii, p < 0.001
1.: 0.: 4.: .,:: 2-i 41: 41 IT
OSTEOPOROSIS - COMPARATIVE PILOT STUDY
BY ULTRASOUND DATA FROM
A
MW Beckmann’, D Jap’, T Mohrmann’, R Bodden-Heidrich’, D Niederacher’, G Crombach’, D Langeneckhard$, C Ratjen’, HG Bender’; ‘Dept. Ob&Gyn, Heinrich-Heine-Universitat, Moorenstr. 5. 40225 Dusseldorf; 21nst. of Trace Elements Analytic, Schloss Tiirnich, PO Box 4 108.50 I.55 Kerpen, Germany.
0.5~ Caiciltil)
001
dd,
OF
Osteoporosis is a systemic bone disease with a decrease in bone structure and increased risk of fractures. For Germany 1995 in women > 65 years approximately 55.000 hip fractures with high morbidity and mortality depend on osteoporosis. The primary diagnosis of osteoporosis and the surveillance of therapeutic interventions is based either on laboratory parameter’s [i.e. alk. phosphatase (Al’), osteocalcin (OC), desoxypyridinolin (DP)] or on radiology [i.e. dual energy X-ray absorptiometry (DXA)]. In a pilot stud encompassing 433 persons [92 volunteers (42 female, 50 male); 34 I patients (101 pre-, 173 postmenopausal; 72 male)] the routine use of ultrasound osteodensitometrie (UD. Lunar AchillesTm) of the OS calcaneus was validated and tested. Velocity of the ultrasound signal (speed of sound = SOS) and the frequency attenuation (broadband ultrasound attenuation = BUA) were measured and a proprietary index (stiffness) calculated. UD data of different groups were analysed and compared with (1) anamnestic data, (2) routine laboratory data, (3) hormones (E2, Pg, FSH, LH, DHEAS, T), (4) bone metabolism parameters (AP, OC, DP), (5) trace elements in hairs (Ca, Gallium), (6) Vit. D and estrogen receptor polymorphism and (7) DXA measurements.
1
Conclusion Vitamin D Metabolites (Calcitriol or 1 Alfacalcidol) are highly effective in stopping the fast trabecular bone loss in postmenopausal osteoporotic women and are therefore an alternative to estrogens.
Continued
93